A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight

• Bimagrumab (Drug), also known as LY3985863, BYM338, VER201: Administered SC
• Tirzepatide (Drug), also known as LY3298176: Administered SC
• Bimagrumab Placebo (Drug): Administered SC
• Tirzepatide Placebo (Drug): Administered SC

Primary outcomes

• Percent Change from Baseline in Body Weight [Baseline, Week 24]

Secondary outcomes

• Percent Change from Baseline in Total Body Fat Mass by Dual-Energy X-Ray Absorptiometry (DXA) [Baseline, Week 24, Week 48]
• Change from Baseline in Body Weight [Baseline, Week 24, Week 48]
• Percentage of Participants Achieving ≥5% Body Weight Reduction [Baseline, Week 24, Week 48]
• Percentage of Participants Achieving ≥10% Body Weight Reduction [Baseline, Week 24, Week 48]
• Percentage of Participants Achieving ≥15% Body Weight Reduction [Baseline, Week 24, Week 48]
• Change from Baseline in Waist Circumference [Baseline, Week 24, Week 48]
• Change from Baseline in Body Mass Index (BMI) [Baseline, Week 24, Week 48]
• Change from Baseline in Waist-to-Height Ratio (WHtR) [Baseline, Week 24, Week 48]
• Percent Change from Baseline in Visceral Adipose Tissue (VAT) [Baseline, Week 24, Week 48]
• Percent Change from Baseline in Total Body Lean Mass by DXA [Baseline, Week 24, Week 48]

Sex: All, ages: 18 Years to 75 Years

Inclusion Criteria:

* Have a BMI of

  * ≥30 kilograms per square meter (kg/m2) or
  * ≥27 kg/m2 and <30 kg/m2, with at least one of the following weight-related comorbidities:

    * Hypertension
    * Dyslipidemia
    * Cardiovascular disease
    * Obstructive sleep apnea
* Have had a stable body weight for the 3 months prior to randomization (<5% body weight gain and/or loss)

Exclusion Criteria:

* Have a prior or planned surgical treatment for obesity
* Have at least one laboratory value suggestive of diabetes during screening
* Use of metformin, or any other glucose-lowering medications
* Have Type 1 Diabetes, latent autoimmune diabetes, been diagnosed with any form of diabetes mellitus except for a prior diagnosis of gestational diabetes mellitus, or history of ketoacidosis or hyperosmolar coma
* Have poorly controlled hypertension
* Have any of the following cardiovascular conditions within 3 months prior to screening:

  * acute myocardial infarction
  * cerebrovascular accident (stroke)
  * unstable angina, or
  * hospitalization due to congestive heart failure
* Have ongoing or a history of frequent intermittent or chronic tachyarrhythmia syndromes
* Have ongoing or a history of bradyarrhythmias other than sinus bradycardia
* Have a history of New York Heart Association (NYHA) Functional Classification III or IV congestive heart failure
* Have a history of symptomatic gallbladder disease within the past 2 years
* Have signs and symptoms of any liver disease
* Have a disease or condition known to cause gastrointestinal malabsorption or a known clinically significant gastric emptying abnormality
* Have a history of acute or chronic pancreatitis
* Have renal impairment, measured as estimated glomerular filtration rate <30 mL/minute/1.73 m2
* Currently taking or have taken medications that may cause significant weight gain or promote weight loss within 3 months prior to screening

• Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), Study director, Eli Lilly and Company